ID   ARBK1_HUMAN             Reviewed;         689 AA.
AC   P25098; B0ZBE1; Q13837; Q6GTT3;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   12-OCT-2022, entry version 228.
DE   RecName: Full=Beta-adrenergic receptor kinase 1;
DE            Short=Beta-ARK-1;
DE            EC=2.7.11.15 {ECO:0000269|PubMed:19715378};
DE   AltName: Full=G-protein coupled receptor kinase 2 {ECO:0000312|HGNC:HGNC:289};
GN   Name=GRK2 {ECO:0000312|HGNC:HGNC:289}; Synonyms=ADRBK1, BARK, BARK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2037065; DOI=10.1016/0014-5793(91)80568-n;
RA   Benovic J.L., Stone W.C., Huebner K., Croce C., Caron M.G., Lefkowitz R.J.;
RT   "cDNA cloning and chromosomal localization of the human beta-adrenergic
RT   receptor kinase.";
RL   FEBS Lett. 283:122-126(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=1339451; DOI=10.1016/s0021-9258(19)50511-7;
RA   Chuang T.T., Sallese M., Ambrosini G., Parruti G., de Blasi A.;
RT   "High expression of beta-adrenergic receptor kinase in human peripheral
RT   blood leukocytes. Isoproterenol and platelet activating factor can induce
RT   kinase translocation.";
RL   J. Biol. Chem. 267:6886-6892(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8195124; DOI=10.1016/s0021-9258(17)36554-7;
RA   Penn R.B., Benovic J.L.;
RT   "Structure of the human gene encoding the beta-adrenergic receptor
RT   kinase.";
RL   J. Biol. Chem. 269:14924-14930(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=PNS, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH ARRB1.
RX   PubMed=9501202; DOI=10.1073/pnas.95.6.2985;
RA   Aragay A.M., Mellado M., Frade J.M., Martin A.M., Jimenez-Sainz M.C.,
RA   Martinez-A C., Mayor F. Jr.;
RT   "Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization
RT   mediated by the G protein-coupled receptor kinase 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:2985-2990(1998).
RN   [7]
RP   INTERACTION WITH CCR5, AND TISSUE SPECIFICITY.
RX   PubMed=10085131; DOI=10.1074/jbc.274.13.8875;
RA   Oppermann M., Mack M., Proudfoot A.E., Olbrich H.;
RT   "Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5)
RT   phosphorylation and identification of phosphorylation sites on the CCR5
RT   carboxyl terminus.";
RL   J. Biol. Chem. 274:8875-8885(1999).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-670, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH ADRB2, SITES REQUIRED FOR
RP   RECEPTOR PHOSPHORYLATION, AND MUTAGENESIS OF ASP-3; LEU-4; GLU-5;
RP   7-VAL-ALA-8 AND ASP-10.
RX   PubMed=19715378; DOI=10.1021/bi900408g;
RA   Pao C.S., Barker B.L., Benovic J.L.;
RT   "Role of the amino terminus of G protein-coupled receptor kinase 2 in
RT   receptor phosphorylation.";
RL   Biochemistry 48:7325-7333(2009).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH LPAR1; LPAR2 AND RALA.
RX   PubMed=19306925; DOI=10.1016/j.cellsig.2009.03.011;
RA   Aziziyeh A.I., Li T.T., Pape C., Pampillo M., Chidiac P., Possmayer F.,
RA   Babwah A.V., Bhattacharya M.;
RT   "Dual regulation of lysophosphatidic acid (LPA1) receptor signalling by Ral
RT   and GRK.";
RL   Cell. Signal. 21:1207-1217(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-670, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION.
RX   PubMed=30284927; DOI=10.1152/ajplung.00135.2018;
RA   Yim P.D., Gallos G., Perez-Zoghbi J.F., Zhang Y., Xu D., Wu A.,
RA   Berkowitz D.E., Emala C.W.;
RT   "Airway smooth muscle photorelaxation via opsin receptor activation.";
RL   Am. J. Physiol. 316:L82-L93(2019).
RN   [14]
RP   STRUCTURE BY NMR OF 552-670.
RX   PubMed=9446593; DOI=10.1074/jbc.273.5.2835;
RA   Fushman D., Najmabadi-Haske T., Cahill S., Zheng J., Levine H. III,
RA   Cowburn D.;
RT   "The solution structure and dynamics of the pleckstrin homology domain of G
RT   protein-coupled receptor kinase 2 (beta-adrenergic receptor kinase 1). A
RT   binding partner of Gbetagamma subunits.";
RL   J. Biol. Chem. 273:2835-2843(1998).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-184 AND GLN-578.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Specifically phosphorylates the agonist-occupied form of the
CC       beta-adrenergic and closely related receptors, probably inducing a
CC       desensitization of them (PubMed:19715378). Key regulator of LPAR1
CC       signaling (PubMed:19306925). Competes with RALA for binding to LPAR1
CC       thus affecting the signaling properties of the receptor
CC       (PubMed:19306925). Desensitizes LPAR1 and LPAR2 in a phosphorylation-
CC       independent manner (PubMed:19306925). Positively regulates ciliary
CC       smoothened (SMO)-dependent Hedgehog (Hh) signaling pathway by
CC       facilitating the trafficking of SMO into the cilium and the stimulation
CC       of SMO activity (By similarity). Inhibits relaxation of airway smooth
CC       muscle in response to blue light (PubMed:30284927).
CC       {ECO:0000250|UniProtKB:P21146, ECO:0000269|PubMed:19306925,
CC       ECO:0000269|PubMed:19715378, ECO:0000269|PubMed:30284927}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[beta-adrenergic receptor] + ATP = [beta-adrenergic receptor]-
CC         phosphate + ADP + H(+); Xref=Rhea:RHEA:19429, Rhea:RHEA-COMP:11222,
CC         Rhea:RHEA-COMP:11223, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, ChEBI:CHEBI:456216;
CC         EC=2.7.11.15; Evidence={ECO:0000269|PubMed:19715378};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19430;
CC         Evidence={ECO:0000305|PubMed:19715378};
CC   -!- ACTIVITY REGULATION: In contrast to other AGC family kinases, the
CC       catalytic activity is solely regulated by the binding of substrates and
CC       ligands, not by phosphorylation of the kinase domain.
CC       {ECO:0000250|UniProtKB:P21146}.
CC   -!- SUBUNIT: Interacts with the heterodimer formed by GNB1 and GNG2 (By
CC       similarity). Interacts with GIT1 (By similarity). Interacts with, and
CC       phosphorylates chemokine-stimulated CCR5 (PubMed:10085131). Interacts
CC       with ARRB1 (PubMed:9501202). Interacts with LPAR1 and LPAR2
CC       (PubMed:19306925). Interacts with RALA in response to LPAR1 activation
CC       (PubMed:19306925). ADRBK1 and RALA mutually inhibit each other's
CC       binding to LPAR1 (PubMed:19306925). Interacts with ADRB2
CC       (PubMed:19715378). {ECO:0000250|UniProtKB:P21146,
CC       ECO:0000250|UniProtKB:P26817, ECO:0000269|PubMed:19715378}.
CC   -!- INTERACTION:
CC       P25098; P05067: APP; NbExp=3; IntAct=EBI-3904795, EBI-77613;
CC       P25098; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-3904795, EBI-9087876;
CC       P25098; P21860: ERBB3; NbExp=3; IntAct=EBI-3904795, EBI-720706;
CC       P25098; P21462: FPR1; NbExp=3; IntAct=EBI-3904795, EBI-2869495;
CC       P25098; Q9Y2X7: GIT1; NbExp=5; IntAct=EBI-3904795, EBI-466061;
CC       P25098; P35626: GRK3; NbExp=2; IntAct=EBI-3904795, EBI-2875868;
CC       P25098; Q00987: MDM2; NbExp=4; IntAct=EBI-3904795, EBI-389668;
CC       P25098; P13591: NCAM1; NbExp=3; IntAct=EBI-3904795, EBI-2846607;
CC       P25098; P25963: NFKBIA; NbExp=2; IntAct=EBI-3904795, EBI-307386;
CC       P25098; Q13635: PTCH1; NbExp=2; IntAct=EBI-3904795, EBI-8775406;
CC       P25098; P0CG48: UBC; NbExp=3; IntAct=EBI-3904795, EBI-3390054;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P26817}. Cell
CC       membrane {ECO:0000250|UniProtKB:P21146}. Postsynapse
CC       {ECO:0000250|UniProtKB:P26817}. Presynapse
CC       {ECO:0000250|UniProtKB:P26817}.
CC   -!- TISSUE SPECIFICITY: Expressed in peripheral blood leukocytes.
CC       {ECO:0000269|PubMed:10085131}.
CC   -!- DOMAIN: The PH domain binds anionic phospholipids and helps recruiting
CC       ADRBK1 from the cytoplasm to plasma membrane close to activated
CC       receptors. It mediates binding to G protein beta and gamma subunits,
CC       competing with G-alpha subunits and other G-betagamma effectors.
CC       {ECO:0000250|UniProtKB:P21146}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. GPRK subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Beta adrenergic receptor kinase
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Beta_Adrenergic_Receptor_Kinase";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X61157; CAA43470.1; -; mRNA.
DR   EMBL; M80776; AAA58391.1; -; mRNA.
DR   EMBL; U08438; AAB60689.1; -; Genomic_DNA.
DR   EMBL; U08435; AAB60689.1; JOINED; Genomic_DNA.
DR   EMBL; U08436; AAB60689.1; JOINED; Genomic_DNA.
DR   EMBL; U08437; AAB60689.1; JOINED; Genomic_DNA.
DR   EMBL; EU326303; ACA05909.1; -; Genomic_DNA.
DR   EMBL; BC037963; AAH37963.1; -; mRNA.
DR   EMBL; BC090863; AAH90863.1; -; mRNA.
DR   CCDS; CCDS8156.1; -.
DR   PIR; A53791; A53791.
DR   RefSeq; NP_001610.2; NM_001619.3.
DR   PDB; 1BAK; NMR; -; A=556-670.
DR   PDB; 3CIK; X-ray; 2.75 A; A=1-689.
DR   PDB; 3KRW; X-ray; 2.90 A; A=2-689.
DR   PDB; 3KRX; X-ray; 3.10 A; A=2-689.
DR   PDB; 3V5W; X-ray; 2.07 A; A=1-689.
DR   PDB; 4MK0; X-ray; 2.40 A; A=30-668.
DR   PDB; 4PNK; X-ray; 2.56 A; A=1-689.
DR   PDB; 5HE1; X-ray; 3.15 A; A=29-670.
DR   PDB; 5UKK; X-ray; 2.60 A; A=30-671.
DR   PDB; 5UKL; X-ray; 2.15 A; A=30-671.
DR   PDB; 5UUU; X-ray; 2.70 A; A=23-538.
DR   PDB; 5UVC; X-ray; 2.65 A; A=23-538.
DR   PDB; 5WG3; X-ray; 2.90 A; A=1-689.
DR   PDB; 5WG4; X-ray; 2.31 A; A=1-689.
DR   PDB; 5WG5; X-ray; 3.10 A; A=1-689.
DR   PDB; 6C2Y; X-ray; 2.74 A; A=1-689.
DR   PDB; 6U7C; X-ray; 2.44 A; A=1-689.
DR   PDB; 7K7L; X-ray; 2.54 A; A=30-668.
DR   PDB; 7K7Z; X-ray; 2.61 A; A=30-668.
DR   PDB; 7PWD; X-ray; 2.60 A; A=1-689.
DR   PDBsum; 1BAK; -.
DR   PDBsum; 3CIK; -.
DR   PDBsum; 3KRW; -.
DR   PDBsum; 3KRX; -.
DR   PDBsum; 3V5W; -.
DR   PDBsum; 4MK0; -.
DR   PDBsum; 4PNK; -.
DR   PDBsum; 5HE1; -.
DR   PDBsum; 5UKK; -.
DR   PDBsum; 5UKL; -.
DR   PDBsum; 5UUU; -.
DR   PDBsum; 5UVC; -.
DR   PDBsum; 5WG3; -.
DR   PDBsum; 5WG4; -.
DR   PDBsum; 5WG5; -.
DR   PDBsum; 6C2Y; -.
DR   PDBsum; 6U7C; -.
DR   PDBsum; 7K7L; -.
DR   PDBsum; 7K7Z; -.
DR   PDBsum; 7PWD; -.
DR   AlphaFoldDB; P25098; -.
DR   SMR; P25098; -.
DR   BioGRID; 106665; 85.
DR   DIP; DIP-42429N; -.
DR   IntAct; P25098; 34.
DR   MINT; P25098; -.
DR   STRING; 9606.ENSP00000312262; -.
DR   BindingDB; P25098; -.
DR   ChEMBL; CHEMBL4079; -.
DR   DrugBank; DB00171; ATP.
DR   DrugCentral; P25098; -.
DR   GuidetoPHARMACOLOGY; 1466; -.
DR   iPTMnet; P25098; -.
DR   PhosphoSitePlus; P25098; -.
DR   BioMuta; GRK2; -.
DR   DMDM; 126302521; -.
DR   EPD; P25098; -.
DR   jPOST; P25098; -.
DR   MassIVE; P25098; -.
DR   MaxQB; P25098; -.
DR   PaxDb; P25098; -.
DR   PeptideAtlas; P25098; -.
DR   PRIDE; P25098; -.
DR   ProteomicsDB; 54254; -.
DR   Antibodypedia; 16429; 719 antibodies from 41 providers.
DR   DNASU; 156; -.
DR   Ensembl; ENST00000308595.10; ENSP00000312262.5; ENSG00000173020.11.
DR   GeneID; 156; -.
DR   KEGG; hsa:156; -.
DR   MANE-Select; ENST00000308595.10; ENSP00000312262.5; NM_001619.5; NP_001610.2.
DR   UCSC; uc009yrn.2; human.
DR   CTD; 156; -.
DR   DisGeNET; 156; -.
DR   GeneCards; GRK2; -.
DR   HGNC; HGNC:289; GRK2.
DR   HPA; ENSG00000173020; Tissue enhanced (bone).
DR   MalaCards; GRK2; -.
DR   MIM; 109635; gene.
DR   neXtProt; NX_P25098; -.
DR   OpenTargets; ENSG00000173020; -.
DR   PharmGKB; PA40; -.
DR   VEuPathDB; HostDB:ENSG00000173020; -.
DR   eggNOG; KOG0986; Eukaryota.
DR   GeneTree; ENSGT00940000161626; -.
DR   InParanoid; P25098; -.
DR   OMA; FIQRSPN; -.
DR   OrthoDB; 1104340at2759; -.
DR   PhylomeDB; P25098; -.
DR   TreeFam; TF313940; -.
DR   BRENDA; 2.7.11.15; 2681.
DR   PathwayCommons; P25098; -.
DR   Reactome; R-HSA-111933; Calmodulin induced events.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-5635838; Activation of SMO.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   SignaLink; P25098; -.
DR   SIGNOR; P25098; -.
DR   BioGRID-ORCS; 156; 59 hits in 1121 CRISPR screens.
DR   ChiTaRS; GRK2; human.
DR   EvolutionaryTrace; P25098; -.
DR   GeneWiki; Beta_adrenergic_receptor_kinase; -.
DR   GenomeRNAi; 156; -.
DR   Pharos; P25098; Tchem.
DR   PRO; PR:P25098; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P25098; protein.
DR   Bgee; ENSG00000173020; Expressed in granulocyte and 149 other tissues.
DR   ExpressionAtlas; P25098; baseline and differential.
DR   Genevisible; P25098; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0005929; C:cilium; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098794; C:postsynapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0098793; C:presynapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0031694; F:alpha-2A adrenergic receptor binding; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0047696; F:beta-adrenergic receptor kinase activity; TAS:Reactome.
DR   GO; GO:0031755; F:Edg-2 lysophosphatidic acid receptor binding; IDA:UniProtKB.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IBA:GO_Central.
DR   GO; GO:0004703; F:G protein-coupled receptor kinase activity; IMP:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; ISS:BHF-UCL.
DR   GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0002029; P:desensitization of G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007213; P:G protein-coupled acetylcholine receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:1901081; P:negative regulation of relaxation of smooth muscle; IMP:UniProtKB.
DR   GO; GO:0045988; P:negative regulation of striated muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0003108; P:negative regulation of the force of heart contraction by chemical signal; IMP:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IEA:Ensembl.
DR   GO; GO:0033605; P:positive regulation of catecholamine secretion; ISS:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0009966; P:regulation of signal transduction; IBA:GO_Central.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IBA:GO_Central.
DR   GO; GO:0007217; P:tachykinin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:CACAO.
DR   GO; GO:0019079; P:viral genome replication; IMP:CACAO.
DR   Gene3D; 1.10.167.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000239; GPCR_kinase.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016137; RGS.
DR   InterPro; IPR036305; RGS_sf.
DR   InterPro; IPR044926; RGS_subdomain_2.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00615; RGS; 1.
DR   PRINTS; PR00717; GPCRKINASE.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00315; RGS; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48097; SSF48097; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50132; RGS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Cell projection; Cytoplasm;
KW   Kinase; Membrane; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Synapse; Transferase.
FT   CHAIN           1..689
FT                   /note="Beta-adrenergic receptor kinase 1"
FT                   /id="PRO_0000085627"
FT   DOMAIN          54..175
FT                   /note="RGS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00171"
FT   DOMAIN          191..453
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          454..521
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          558..652
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   REGION          1..190
FT                   /note="N-terminal"
FT   ACT_SITE        317
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         197..205
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         220
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            3
FT                   /note="Required for receptor phosphorylation"
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   SITE            4
FT                   /note="Required for receptor phosphorylation"
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   SITE            10
FT                   /note="Required for receptor phosphorylation"
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   MOD_RES         670
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:23186163"
FT   VARIANT         184
FT                   /note="I -> T (in dbSNP:rs55696045)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040378"
FT   VARIANT         578
FT                   /note="R -> Q (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040379"
FT   MUTAGEN         3
FT                   /note="D->A: 85% reduction in phosphorylation of G-protein
FT                   coupled receptor rhodopsin."
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   MUTAGEN         3
FT                   /note="D->K: 95% reduction in phosphorylation of G-protein
FT                   coupled receptor rhodopsin. 60% reduction in
FT                   phosphorylation of beta-2 adrenergic receptor ADRB2. Does
FT                   not affect binding to ADRB2. Not activated by receptor
FT                   binding. No effect on phosphorylation of the non-receptor
FT                   substrate tubulin."
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   MUTAGEN         3
FT                   /note="D->N: 60% reduction in phosphorylation of G-protein
FT                   coupled receptor rhodopsin."
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   MUTAGEN         4
FT                   /note="L->A: 95% reduction in phosphorylation of G-protein
FT                   coupled receptor rhodopsin. 90% reduction in
FT                   phosphorylation of beta-2 adrenergic receptor ADRB2. Does
FT                   not affect binding to ADRB2. Not activated by receptor
FT                   binding. No effect on phosphorylation of the non-receptor
FT                   substrate tubulin."
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   MUTAGEN         4
FT                   /note="L->K: 95% reduction in phosphorylation of G-protein
FT                   coupled receptor rhodopsin."
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   MUTAGEN         5
FT                   /note="E->A: 50% reduction in phosphorylation of G-protein
FT                   coupled receptor rhodopsin."
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   MUTAGEN         7..8
FT                   /note="VL->AA: 95% reduction in phosphorylation of
FT                   G-protein coupled receptor rhodopsin."
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   MUTAGEN         10
FT                   /note="D->A: 95% reduction in phosphorylation of G-protein
FT                   coupled receptor rhodopsin and beta-2 adrenergic receptor
FT                   ADRB2. Does not affect binding to ADRB2. Not activated by
FT                   receptor binding. No effect on phosphorylation of the
FT                   non-receptor substrate tubulin."
FT                   /evidence="ECO:0000269|PubMed:19715378"
FT   CONFLICT        168..185
FT                   /note="SDKFTRFCQWKNVELNIH -> RISSHGFASGRMWSSTST (in Ref. 3;
FT                   AAB60689)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        211
FT                   /note="A -> R (in Ref. 1; CAA43470 and 3; AAB60689)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        422
FT                   /note="R -> H (in Ref. 1; CAA43470 and 3; AAB60689)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        465
FT                   /note="K -> R (in Ref. 1; CAA43470)"
FT                   /evidence="ECO:0000305"
FT   HELIX           39..49
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           55..59
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           62..75
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           77..79
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           80..93
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           98..109
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           112..118
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          119..122
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           126..137
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            143..146
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           147..157
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           160..167
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           169..181
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           188..190
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          191..199
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          201..210
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            211..213
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          216..223
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           224..229
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           233..246
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          247..249
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          252..254
FT                   /evidence="ECO:0007829|PDB:3KRW"
FT   STRAND          257..262
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          264..271
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          276..278
FT                   /evidence="ECO:0007829|PDB:5HE1"
FT   HELIX           279..286
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           291..309
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            310..312
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           320..322
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          323..325
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          327..329
FT                   /evidence="ECO:0007829|PDB:5WG4"
FT   STRAND          331..333
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           336..338
FT                   /evidence="ECO:0007829|PDB:3CIK"
FT   STRAND          343..345
FT                   /evidence="ECO:0007829|PDB:5WG4"
FT   HELIX           354..356
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           359..362
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          363..365
FT                   /evidence="ECO:0007829|PDB:7K7L"
FT   HELIX           371..386
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          390..392
FT                   /evidence="ECO:0007829|PDB:5WG5"
FT   HELIX           393..395
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           399..408
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          415..417
FT                   /evidence="ECO:0007829|PDB:3KRW"
FT   HELIX           419..428
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           433..435
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          440..442
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           444..447
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           451..453
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           458..462
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            477..480
FT                   /evidence="ECO:0007829|PDB:5UKL"
FT   TURN            492..495
FT                   /evidence="ECO:0007829|PDB:5UUU"
FT   HELIX           500..503
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            504..508
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           514..522
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            523..525
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           526..546
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          555..557
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          561..568
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            571..573
FT                   /evidence="ECO:0007829|PDB:5UKL"
FT   STRAND          577..584
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          587..591
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          593..595
FT                   /evidence="ECO:0007829|PDB:4MK0"
FT   STRAND          599..602
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           603..605
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          606..616
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          618..624
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            625..627
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   STRAND          628..633
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   HELIX           637..658
FT                   /evidence="ECO:0007829|PDB:3V5W"
FT   TURN            662..664
FT                   /evidence="ECO:0007829|PDB:3V5W"
SQ   SEQUENCE   689 AA;  79574 MW;  4DB68F62841AFA7D CRC64;
     MADLEAVLAD VSYLMAMEKS KATPAARASK KILLPEPSIR SVMQKYLEDR GEVTFEKIFS
     QKLGYLLFRD FCLNHLEEAR PLVEFYEEIK KYEKLETEEE RVARSREIFD SYIMKELLAC
     SHPFSKSATE HVQGHLGKKQ VPPDLFQPYI EEICQNLRGD VFQKFIESDK FTRFCQWKNV
     ELNIHLTMND FSVHRIIGRG GFGEVYGCRK ADTGKMYAMK CLDKKRIKMK QGETLALNER
     IMLSLVSTGD CPFIVCMSYA FHTPDKLSFI LDLMNGGDLH YHLSQHGVFS EADMRFYAAE
     IILGLEHMHN RFVVYRDLKP ANILLDEHGH VRISDLGLAC DFSKKKPHAS VGTHGYMAPE
     VLQKGVAYDS SADWFSLGCM LFKLLRGHSP FRQHKTKDKH EIDRMTLTMA VELPDSFSPE
     LRSLLEGLLQ RDVNRRLGCL GRGAQEVKES PFFRSLDWQM VFLQKYPPPL IPPRGEVNAA
     DAFDIGSFDE EDTKGIKLLD SDQELYRNFP LTISERWQQE VAETVFDTIN AETDRLEARK
     KAKNKQLGHE EDYALGKDCI MHGYMSKMGN PFLTQWQRRY FYLFPNRLEW RGEGEAPQSL
     LTMEEIQSVE ETQIKERKCL LLKIRGGKQF ILQCDSDPEL VQWKKELRDA YREAQQLVQR
     VPKMKNKPRS PVVELSKVPL VQRGSANGL
//
